Developing new orphan therapies, increasing access to existing life-saving treatments, and lowering costs is a moral imperative. However, major challenges remain for the rare disease community to achieve these goals.
Maximizing Clinical Trial Access, Diversity, and Efficiency are Keys to Optimizing Orphan Drug Development
